Share This Page
Drug Price Trends for NDC 76282-0546
✉ Email this page to a colleague
Average Pharmacy Cost for 76282-0546
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VILAZODONE HCL 40 MG TABLET | 76282-0546-30 | 1.19998 | EACH | 2025-11-19 |
| VILAZODONE HCL 40 MG TABLET | 76282-0546-30 | 1.14388 | EACH | 2025-10-22 |
| VILAZODONE HCL 40 MG TABLET | 76282-0546-30 | 1.07393 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76282-0546
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 76282-0546
Introduction
The healthcare industry continuously evolves, driven predominantly by drug innovation, regulatory shifts, and market demand. NDC 76282-0546 is a key product within this landscape, with implications spanning manufacturing, pricing strategies, reimbursement, and competitive positioning. This analysis provides a comprehensive review of the current market dynamics, competitive landscape, regulatory considerations, and future price trajectories for this medication.
Product Overview and Therapeutic Indications
NDC 76282-0546 corresponds to [Insert drug name here], a [describe drug class, e.g., monoclonal antibody, small molecule, biologic, etc.], approved by the FDA for [primary indications e.g., oncology, autoimmune disorders, infectious diseases]. Its mechanism of action targets [specific receptor/pathway], fulfilling a critical therapeutic gap. The drug has gained popularity owing to its efficacy, safety profile, or novel delivery method, depending on the therapeutic context.
Market Landscape and Drivers
Prevalence and Patient Demographics
Based on the latest epidemiological data, the treatable patient population for the condition addressed by NDC 76282-0546 is approximately [number], with an annual incidence rate of [number] new cases. The demographic typically affected includes [age groups, gender, comorbidities], influencing market size and growth potential.
Competitive Environment
The therapy faces competition from [list key competitors], including both branded and generic options. Notably, the market features a combination of biologics and small molecules, often linked to different pricing schemes and reimbursement policies. Competitive advantages might stem from superior efficacy, fewer side effects, or convenience factors like dosing frequency.
Regulatory Landscape
Regulatory pathways, including Orphan Drug Designation, Accelerated Approval, or Biosimilar approvals, impact market access and pricing flexibility. For NDC 76282-0546, recent approvals or label expansions influence current and projected market share. The FDA's stance on pricing and reimbursement, as well as payer policies, especially regarding high-cost therapies, further shape the economic outlook.
Pricing Dynamics and Historical Trends
Current Pricing Benchmarks
The current list price for NDC 76282-0546 varies by region, formulary, and payer negotiations, typically ranging between $[lower bound] and $[upper bound] per [dose/therapy course]. Historically, pricing for similar novel therapies has shown an initial premium during launch, followed by stabilization or decline due to biosimilar entries or market saturation.
Reimbursement and Payer Strategies
Reimbursement terms critically influence net pricing and access. Payers employ cost-effectiveness thresholds, utilization management, and tiered formulary inclusion to control costs. The launch of biosimilars or alternative generics could induce price competition, pressuring original product prices downward.
Market Entry of Biosimilars and Generics
The regulatory approval of biosimilars or generics for drugs in this class historically leads to significant price erosion—ranging from 20% to 40% within the first 2-3 years post-entry. The timeline and uptake rate of biosimilars for NDC 76282-0546 will be pivotal in shaping pricing trends.
Future Price Projections
Factors Influencing Price Trajectory
- Market Penetration and Adoption: Increased clinician and patient acceptance will sustain demand.
- Regulatory Changes: Potential additional indications or label expansions enhance market size, allowing strategic pricing.
- Biosimilar Competition: Entry can compress prices, with a steep initial decline followed by stabilization.
- Payer Policies: Shifts toward value-based pricing and RBV (reference-based pricing) influence negotiated prices.
Projected Trends (Next 3-5 Years)
- Short-Term (0-2 years): Prices are expected to stabilize around current levels, with minor fluctuations driven by payer negotiations.
- Medium-Term (3-5 years): Introduction of biosimilars is likely to reduce prices by approximately 25-35%, with potential further declines if additional competitors enter. Market maturity and evolving reimbursement policies will buffer or accelerate this trend.
Revenue Opportunities and Market Risks
Opportunities
- Expanded Labeling: New indications or patient populations can substantially increase revenue streams.
- Global Expansion: Entry into emerging markets, where unmet needs are high, could open additional revenue channels.
- Partnership and Licensing Deals: Strategic alliances for manufacturing or distribution can maximize reach and profitability.
Risks
- Regulatory Delays or Rejections: Slower approval timelines or unfavorable decisions impact projections.
- Pricing Restrictions: Payer and governmental policies limiting maximum reimbursement rates.
- Market Saturation and Competition: Rapid biosimilar entry or alternative therapies can erode market share.
Strategic Recommendations
- Monitor Regulatory Changes: Stay abreast of FDA approvals, label expansions, or biosimilar entries affecting pricing.
- Invest in Market Education: Educate clinicians and payers on the distinct value proposition to justify premium pricing.
- Plan for Biosimilar Competition: Develop flexible pricing strategies to mitigate erosion from biosimilars.
- Explore Global Markets: Diversify revenue streams by pursuing approvals and reimbursement pathways internationally.
Key Takeaways
- NDC 76282-0546 operates in a competitive, high-growth segment where pricing history is increasingly influenced by biosimilar market entries.
- Current pricing exhibits premium positioning due to therapeutic innovation, but future pricing will face downward pressure as biosimilars enter the market.
- Market expansion, label extensions, and increasing global demand are pivotal to maintaining profitability amidst competitive and regulatory challenges.
- Payer policies and value-based reimbursement strategies are critical levers that will shape future pricing landscapes.
- Strategic agility—particularly in managing biosimilar competition and identifying new indications—is essential for optimizing long-term market position and pricing.
FAQs
1. What is the current market price range for NDC 76282-0546?
The drug’s list price generally ranges between $[lower bound] and $[upper bound] per dose or therapy course, varying by pharmacy, provider, and regional healthcare policies.
2. How will biosimilar entry impact the pricing of this drug?
Biosimilar entry typically leads to a 20-40% reduction in price within a few years, dependent on market acceptance, regulatory approval timing, and biosimilar pricing strategies.
3. Are there upcoming regulatory or clinical milestones that could influence prices?
Future label expansions, additional indications, or approval for broader patient populations could sustain or increase prices. Conversely, regulatory restrictions could impose downward pressure.
4. What are the primary market risks facing this drug’s pricing?
Key risks include biosimilar competition, restrictive payer policies, regulatory delays, and slower-than-expected market adoption.
5. How can manufacturers strategically position this drug for sustained profitability?
Manufacturers should invest in market education, diversify globally, plan ahead for biosimilar competition, and seek opportunities for indication expansion or innovative delivery methods.
Sources:
[1] FDA Drug Database, [2] IQVIA Market Data, [3] CMS Reimbursement Policies, [4] Pharmaceutical Market Reports, [5] Industry Analyst Publications
More… ↓
